FDA Approves First Oral Blood Thinning Medication for Children | FDA

“The U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days. The FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism. In addition, Pradaxa was approved in capsule form to treat blood clots in patients eight years and older with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days, and to prevent recurrent clots in patients eight years and older who completed treatment for their first venous thromboembolism. Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth; the only other approved blood thinning medication for children is given by injection.”

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-blood-thinning-medication-children

PRADAXA: WHAT BIG PHARMA WANTS TO GIVE TO CHILDREN WITH ADVERSE THROMBOEMBOLISM FROM THE COVID INJECTIONS, APPROVED BY THE FDA

Boehringer Ingelheim Pharmaceuticals faces more than 2,400 lawsuits in Connecticut state court blaming Pradaxa for severe internal bleeding. The company agreed in 2014 to pay $650 million to settle more than 4,100 federal lawsuits involving similar claims.

The drug is linked to dangerous side effects, including uncontrollable bleeding. Marketing campaigns pushed the idea that the medicine was easy to take and didn’t require monitoring. But internal company documents showed that employees tried to quash a research paper. They feared it would lead to a blood test requirement.”

https://www.drugwatch.com/pradaxa/lawsuits/

Hmm. I wonder if the approval of this drug has anything to do with blood clotting caused by the COVID injections?

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

Discover more from Lighthouse Economics

Subscribe now to keep reading and get access to the full archive.

Continue reading